公司将持续深耕合成生物学、工业发酵、益生菌、细胞治疗等核心应用场景。其技术不仅能助 力高效菌种筛选与工艺优化，更能为CAR-T等细胞药物和益生菌的研发与质控提供活体、无 损的单细胞代谢动态数据，直击产业对细胞功能量化监控的核心需求。通过提供从仪器到场景 化解决方案的全链条支持，星赛生物正为生物制造体系的升级与细胞药物产业的发展构建坚实 的工具基础。 此前星赛生物共获得 三轮融资 ，分别是： 2023 年 12 月 近 亿 元 人 民 币 A 轮 融 资 ， 由 恒 旭 资 本 领 投 ， 北 洋 海 棠 基 金 跟 投 。 2023 年 7 月 Pre-A轮融资数千万元人民币，投资方包括高科新浚、浙江衡吉。2022年12月由茅台基金公 司管理的茅台科创基金投资进行的 战略融资 。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 青 岛星赛生物科技有限公司（以下简称"星赛生物"）宣布完成近亿元人民币新一轮融 资。 本轮融资将围绕"技术深度融合、智能生态构建、全球市场拓展"三大战略方向，全面推 动星赛生物从"关键技术突破与产品化"阶段 ...

Group 1 - The company is currently in the process of finalizing its financial data for 2025 [1] - According to the company's 2024 annual report, overseas revenue is expected to account for over 30% of the total operating revenue for the year 2024 [1] - The company's business expansion primarily relies on direct sales [1] Group 2 - As of now, the company has not established subsidiaries in EU countries [1] - An investor inquired about the proportion of revenue from the EU region in the company's overall operating income [3] - The investor also asked about the sales methods used for the EU market, specifically whether sales are made directly from domestic entities to EU customers, through subsidiaries, or via third-party traders and agents [3]

药康生物首次公开发行股票的发行费用总额为1.00亿元，其中，保荐承销费8278.75万元。 (责任编辑：马欣) 中国经济网北京1月19日讯 药康生物(688046.SH)今日股价下跌，截至收盘，该股报18.14元，跌幅 4.07%。 药康生物于2022年4月25日在上交所科创板上市，发行价格为22.53元/股，公开发行股票数量5000万 股，保荐机构（主承销商）为华泰联合证券有限责任公司，保荐代表人为季李华、洪捷超。该股目前处 于破发状态。 药康生物首次公开发行股票募集资金总额为11.27亿元，募集资金净额为10.26亿元。药康生物最终募集 资金净额比原计划多2.06亿元。药康生物于2022年4月18日披露的招股说明书显示，该公司拟募集资金 8.20亿元，分别用于模式动物小鼠研发繁育一体化基地建设项目、真实世界动物模型研发及转化平台建 设项目。 ...

BIM-IOL 系统设计为能够持续释放比马前列素长达三年，这是一种前列腺素类似物(PGA)，已于 2001 年获得美国食品药品监督管理局(FDA)批准用于局部治疗，以降低 OAG 或 OHT 患者的高眼内压。此 外，该公司还在开发一种非人工晶状体基础的环形缓释植入物，内含比马前列素，公司认为该植入物可 以独立进行植入手术，为接受过 BIM-IOL 系统治疗的患者提供再次治疗的机会，并为已接受过白内障 手术的 OAG 或 OHT 患者提供长期护理。 该公司总部位于加利福尼亚州阿利索维耶霍，成立于 2019 年，计划在纳斯达克上市，股票代码为 SGP。SpyGlass Pharma 于 2025 年 9 月 26 日秘密提交了上市申请。杰富瑞、里林克合伙公司、花旗和 斯蒂费尔是此次交易的联合主承销商。此次交易的具体定价条款尚未披露。 智通财经APP获悉，SpyGlass Pharma(SGP.US)是一家正处于3期临床试验阶段的生物技术企业，其业务 重心聚焦于研发用于治疗慢性眼疾的植入式医疗器械。上周五，该公司正式向美国证券交易委员会 (SEC)递交了首次公开募股(IPO)申请，拟募集最高达1亿美元的资金。 据了 ...

Market Overview - The Hong Kong stock market experienced a decline, with all three major indices dropping over 1%. The Hang Seng Index fell by 1.05% to 26,563.9 points, with a total trading volume of 225.69 billion HKD [1] - Huatai Securities noted that the core factors driving the market rebound in the first quarter remain unchanged, including overall loose financial conditions and improved profit expectations, suggesting continued opportunities for investment in Hong Kong stocks [1] Blue-Chip Stocks Performance - Li Ning (02331) reached a new high, closing up 2.94% at 21 HKD, contributing 2.21 points to the Hang Seng Index. Morgan Stanley forecasts moderate revenue growth for Li Ning by 2025, with net profit margins stabilizing at high single digits [2] - Other blue-chip stocks included Sinopec (00386) up 3.34% and Mengniu Dairy (02319) up 2.78%, while China Biologic Products (01177) fell 6.19% and Innovent Biologics (01801) dropped 4.64%, negatively impacting the index [2] Sector Highlights Aviation Stocks - Aviation stocks performed well, with China Eastern Airlines (00670) up 9.2%, China Southern Airlines (01055) up 6.29%, and Air China (00753) up 3.76%. The 2026 Spring Festival travel period is expected to see a passenger volume of 95 million, a 5.3% increase year-on-year [3] Power Equipment Stocks - Power equipment stocks rose, with Dongfang Electric (01072) up 6.38% and Harbin Electric (01133) up 5.46%. The National Energy Administration announced that China's electricity consumption is projected to exceed 10 trillion kWh by 2025, a 5% year-on-year increase [4] Gold Stocks - Gold stocks were active, with Zhaojin Mining (01818) up 3.62% and Zijin Mining (02259) up 2.47%. The international gold price surged to a historical high of 4,690 USD per ounce due to rising market risk aversion stemming from escalating US-EU tariff disputes [5] Earnings Forecasts - Companies with positive earnings forecasts saw strong performance, including Qutoutiao (00917) up 38.78% and TCL Electronics (01070) up 13.4%. Qutoutiao expects to turn a profit with a net income between 270 million to 330 million RMB for the fiscal year ending December 31, 2025 [6] Notable Stock Movements - New World Development (00017) surged 16.28% to 11.07 HKD, reaching a two-year high, as the company’s chairman expressed confidence in creating value through strategic investments [7] - UBTECH Robotics (09880) rose 8.63% after signing a service agreement with Airbus for humanoid robots [8] - China National Offshore Oil Corporation (01138) climbed 7.39% amid favorable conditions in the oil transportation market due to geopolitical changes [9] - China Duty Free Group (01880) increased by 6.65% following strong growth in duty-free shopping in Hainan [10] - Cambridge Technology (06166) fell 12.2% after reporting lower-than-expected fourth-quarter profits despite a projected annual profit increase [11]

Core Viewpoint - AgomAb Therapeutics, a Belgium-based biotech company focused on immune and inflammatory diseases, has filed for an IPO to raise up to $100 million [1][2] Group 1: Company Overview - AgomAb Therapeutics specializes in developing innovative disease-modifying therapies for immune and inflammatory diseases [1] - The company was founded in 2017 and is headquartered in Antwerp, Belgium [2] - The lead candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor targeting the TGFβR1 pathway, aimed at treating fibrotic diseases [1] Group 2: Product Pipeline - The primary focus is on treating chronic fibrotic diseases by inhibiting the TGFβ signaling pathway [1] - The second clinical-stage candidate, AGMB-447, is an inhaled small molecule inhibitor targeting TGFβR1, under development for idiopathic pulmonary fibrosis (IPF) [1] Group 3: IPO Details - The company plans to list on NASDAQ under the ticker symbol "AGMB" [2] - The IPO's joint bookrunners include JPMorgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen [2] - Specific pricing terms for the IPO have not yet been disclosed [2]

Core Viewpoint - Daiwa reports that WuXi Biologics (02269) and WuXi AppTec (02268) plan to make a full acquisition offer for at least 60% of the shares of Easton Biopharma (01875) for a maximum cost of approximately 2.8 billion yuan, with the expectation that Easton Biopharma will maintain its listing status after the acquisition [1] Group 1 - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China [1] - The deal aims to enrich the project portfolio and expand the customer base for WuXi AppTec [1] - This acquisition is anticipated to strengthen WuXi AppTec's leading market position in the ADC contract research and manufacturing organization sector [1] Group 2 - Daiwa currently assigns a "Buy" investment rating to WuXi Biologics [1]

Group 1 - The core viewpoint of the article is that WuXi Biologics (02269) and WuXi AppTec (02268) have announced a comprehensive acquisition offer to acquire at least 60% of the shares of Easton Biopharma (01875) for a maximum price of approximately 2.8 billion yuan [1] - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China, further enriching its project portfolio and expanding its customer base [1] - The acquisition is anticipated to solidify WuXi AppTec's leading market position in the field of ADC contract research and manufacturing organizations [1] Group 2 - Daiwa currently gives a "Buy" investment rating for WuXi Biologics [1]

高达8 8%的制药行业受访者表示，AI的整合将给该行业带来"高度"或"极高程度"的颠覆性影 响。这使得生物医药行业的预期受冲击程度高于平均水平，仅次于软件公司。 但值得注意的是，受访者认为AI对其所在企业的颠覆程度较低——4 4%的受访者预计公司层 面受到的冲击将处于"中等"或"较低"水平，这可能反映出企业已在推进AI项目。 AI对行业的颠覆程度 本文来自彭博终端，终端用户可运行NSN T8XFZBKGZAJE 阅读原文。非终端用户可点击文末 "阅读原文" 预约演示。 全球市场版图日新月异，彭博行业研究（Bloomberg Intelligence）为您的企业战略助力。在 制药与生物技术领域，无论是全球行业资讯与热点，还是制药管线里程碑及催化剂事件、财务 预测…… BI涵盖广泛且深度的关键信息，旨在为您的决策提供可靠且具有竞争力的洞见支撑。 扫描二维码 立即订阅 彭博生物制药双周报 本期主题： 药物研发是最易受到AI颠覆性影响的领域之一 （彭博行业研究）——彭博行业研究的跨行业AI调研显示，尽管药物研发企业对AI的实用价 值抱有热情，但在实际应用上仍持谨慎态度，企业预计未来五年药物研发流程中仅有 1 0%- ...

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas issuance and listing, specifically requesting details from Libang Pharmaceutical regarding its previous listing on the Jiangsu Equity Exchange and the reasons for its termination [1] - Libang Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC acting as joint sponsors [1] - The CSRC requires Libang Pharmaceutical to clarify the situation of its major shareholders and any significant impacts on the current issuance and listing process [1] Group 2 - The company must provide detailed explanations regarding its equity structure, including past capital increases and share transfer pricing, to ensure compliance with legal regulations [2] - The company is required to clarify the reasons for any capital reductions and the payment situations involved, ensuring that there are no issues of false capital contributions or tax compliance [2] - The company must also disclose the circumstances surrounding its employee stock ownership plan, including the rationale for any pricing discrepancies and compliance with relevant regulations [3] Group 3 - Libang Pharmaceutical is a leading global biopharmaceutical company focused on kidney disease, with a comprehensive portfolio of innovative products and a significant market potential valued in the hundreds of billions of dollars [3] - The company has established a vertically integrated platform that encompasses research and development, production, and commercialization [3]